Ten-Year Experience with Sublingual Immunotherapy for Juniper Pollenosis
Poster Feb 21, 2015
W Donald Cooke MD
RATIONALE: Juniper species are major spring allergens in the southwestern USA. We previously reported a study of sublingual immunotherapy (SLIT) for Juniper pollenosis
in 2005. Over the last ten years, we have gradually expanded the use of SLIT for this allergen. This study summarizes our results.
METHODS: Pollen counts for J. Asheii and J. Scropulorum typically start to rise in mid- March in our area of southwest Colorado. Patients are contacted in early January to
begin the SLIT program. Patients receive 2 vials of J. Scropulorum (Rocky Mountain Juniper, Greer Labs)) extract containing a total of 150-200 micrograms of protein. Maintenance dose is one dropper (6 micrograms) every 3 or 4 days until late May. Patients are instructed to place the drops under the tongue for at least one to two minutes, and then expectorate the remainder. Pollen counts are observed during the season using a Rotorod sampler. Patients are then contacted by phone or office visit in May for assessment of efficacy.
RESULTS: For the 2014 season, 165 patients were treated with Juniper SLIT. 77 of these
patients were monosensitized. 149 (90%) patients reported positive results. Side effects
were mostly local oral discomfort. There were no systemic reactions. In the 2013 season, there were 53 patients reporting 79% positive results.
CONCLUSIONS: Juniper SLIT may be an effective form of immunotherapy when given pre-co-seasonally at the doses studied.
Genome-wide association studies (GWAS) have identified more than 100 genetic loci associated with type 2 diabetes. The majority of these are located in the intergenic or intragenic regions suggesting that the implicated variants may alter chromatin conformation. This, in turn, is likely to influence the expression of nearby or more remotely located genes to alter beta cell function. At present, however, detailed molecular and functional analyses are still lacking for most of these variants. We recently analysed one of these loci and mapped five causal variants in an islet-specific enhancer cluster within the STARD10 gene locus. Here, we aimed to understand how these causal variants influence b-cell function by alteration of the chromatin structure of enhancer clusterREAD MORE
This abstract discusses three cases of pediatric heart transplant patients who suffered from parvovirus (B19) infection. Of these patients, two ( B & C) responded well to standard intravenous Ig therapy. Patient A however, did not respond to standard treatment and was begun on subcutaneous Ig, which effectively diminished his viral load. Thus, subcutaneous Ig infusions might serve as a second line treatment for transplant patients with parvovirus who do not respond well to the standard approach.READ MORE